Bogong Technology Completes Series A Funding to Advance AI-Driven Digital Health Solutions in Life Sciences
VCBeat has learned that Guangdong Bogong Sanluwu Robot Technology Co., Ltd. (hereinafter referred to as “Bogong Tech”), a provider of AI-plus-life-sciences digital health solutions, has announced the completion of a new round ofSeries AFinancing. This round of financing was led byEndeavor FundLead investor; the funds raised will be used to strengthen product R&D, enhance talent development, and build a resilient supply chain.
Bogong Technology, established in 2022, is an innovative enterprise dedicated to the research and development of robotics in the life sciences sector. It is committed to addressing industry challenges in the digital storage and large-scale manufacturing preparation of stem cells through advanced robotic manufacturing technologies. The company has now established a comprehensive end-to-end layout encompassing R&D systems, supply chain development, mass production, and commercialization.
Liu Zhaoqiang, the founder of Bogong Technology, has 12 years of experience in robot project management and is among the first batch of professionals in China engaged in robot R&D. Dr. Li Tao, the Chief Scientist, brings over 30 years of experience in the research and application of stem cells and immune cells. He is a renowned authority in the field of stem cells and a founding shareholder of Bogong Technology.
Leveraging aerospace and military-grade mechanical components capable of long-term tolerance to deep cryogenic temperatures,
Achieve temperature-fluctuation-free access throughout the entire lifecycle of stored samples
Liu Zhaoqiang told VCBeat that the core of the “AI + Life Sciences” digital health solution is an AI-powered life data management system. The storage of life data resources serves as the cornerstone of human health development and is the fundamental infrastructure for precision medicine and cutting-edge biological research. It is widely applied in fields such as clinical sample collection, epidemiology and public health research, life and health studies, biopharmaceutical sample storage, cell and gene therapy, genetic testing, assisted reproduction, conservation of precious animal and plant resources, and forensic evidence identification.
Many of these precious samples require long-term storage in ultra-low temperature environments at -196°C, making data-driven management and analysis critically important. The Bogong Technology team places addressing customers’ key pain points at the core of its strategy and fully leverages artificial intelligence technologies to enable the implementation of scenario-based solutions.
Since extreme environments capable of achieving cryogenic temperatures are rarely encountered in daily life and work, most conductive structures of devices sourced from traditional industrial supply chains are unable to operate automatically under such extreme conditions.
Bogong Technology has developed the Bogong M9, a domestically produced large-scale AI medical device. Positioned as a fully digital biological sample management and storage system, it is the flagship product of the BODK brand. The Bogong M9 features a breakthrough design that fully integrates aerospace and military-grade mechanical components, capable of long-term resistance to cryogenic conditions, within the low-temperature chamber. It provides flexible ultra-low temperature storage capacity for 30,000 to 60,000 samples, enabling “convenient operation” between storage and working areas, and meeting the requirement for accessing samples throughout their entire lifecycle without temperature fluctuations. This ensures high-level biosafety protection for biological samples without compromising sample quality or interfering with experimental results.
It is reported that Bogong Technology has established its R&D center in the core area of the Greater Bay Area—the Biopharmaceutical Industry Base at Songshan Lake National Science City. Covering an area of over 3,000 square meters, the center features a GMP-compliant cleanroom space exceeding 1,000 square meters for AI-powered stem cell robotics, a life gene testing laboratory of over 1,000 square meters, and a cellular life storage vault integrated with a big data health management center, also surpassing 1,000 square meters. The facility is capable of automatically storing more than 200,000 samples of cellular and biological data resources.
Meanwhile, the company has collaborated with research institutes to establish a full-chain engineering center covering R&D, prototyping, supply chain management, production management, in-process quality control, and after-sales service, achieving a breakthrough in scaling artificial intelligence-based life data management technology from “customization” to “mass production.” This also marks that China possesses fully independent intellectual property rights in the technological development and manufacturing of AI-enabled life data storage devices, laying a solid foundation for capturing overseas markets with next-generation large-scale medical equipment under the “Intelligently Made in China” brand.
Meanwhile, Bogong Technology has also reached a new milestone in its collaborations with the industry.
On April 11, 2024, the signing ceremony for the “Artificial Intelligence + Digital Management of Biological Samples” project, jointly established by the Songshan Lake Materials Laboratory and Bogong Technology, along with the Dongguan Stem Cell and Gene Therapy Industry Development Forum, was successfully held in Songshan Lake, the core area of the Biomedical Industry Demonstration Base.Leveraging the robust scientific research capabilities and technological advantages of the Songshan Lake Materials Laboratory and Guangdong Bogong Sanluwu Robot Technology Co., Ltd., this project focuses on cutting-edge technologies in artificial intelligence and the digitalization of biological samples, aiming to drive innovative development in related industries.
On July 15, 2024, Bogong Technology and Qiyan Medical held a strategic cooperation signing ceremony at the Songshan Lake Biomedical Industry Base, reaching a comprehensive strategic partnership in areas including chronic disease prevention, health management, medical examinations, and anti-aging within the field of geroscience.
Liu Zhaoqiang emphasized that the field of AI-powered medical equipment for life sciences urgently needs pioneers who possess brand awareness and the courage to explore high-end brand markets. Leveraging its unique technological pathway, Bogong Technology has seized the historical opportunity presented by the national push to develop new quality productive forces. Since its inception, the company has established an ambitious strategy to build a high-end medical equipment brand. To implement this strategy, the company’s team has continuously deepened its efforts in key areas such as brand image building and industrial product design. Its core members bring years of valuable experience in the artificial intelligence and life sciences industries, laying a solid foundation for the brand’s journey toward premium positioning.
Regarding the securing of this round of financing,Liu Zhaoqiang, Founder of Bogong TechnologyStatement: A review of the industry’s development over the past years reveals that, with continuous breakthroughs in biotechnology, the global field of digital health equipment for life sciences is in a phase of rapid growth. We have every reason to believe that, fueled by China’s increasingly robust demand for healthcare, the AI + life sciences sector will see the emergence of companies driven by intelligent manufacturing in China. Guided by its mission and vision to “let artificial intelligence enhance the beauty of medicine,” Bogong Technology is striving to become a globally mainstream provider of AI + life sciences medical equipment.
Guo Haobin, Founding Partner of Endeavor FundEndeavor Fund remains bullish on the development opportunities in upstream tools driven by the iterative advancements in life science technologies. Relying on its profound insights into application scenarios, robust technological accumulation, and clear product roadmap, Bogong Technology has achieved domestic surpassing in “Intelligent Manufacturing in China.” Endeavor Fund is honored to partner with Bogong Technology to jointly facilitate the intelligent upgrade and transformation of the life science and health industry. Bogong Technology boasts a top-tier industry team, has developed a highly promising product portfolio within just a few years, and has witnessed rapid growth in its business performance. Meanwhile, we are very optimistic about the field of automated AI-driven life science data management, a critical segment of the life science and health industry, where Bogong Technology’s products deliver unique, industry-leading value.
Zhang Yunpeng, Founding Partner of Qingcheng CapitalStatement: Qingcheng Capital is deeply honored to have accompanied Bogong Technology in its growth journey. Looking ahead, we aim to leverage the ecosystem resources of Qingcheng Capital to support the company and help Bogong Technology become a global leader in the life sciences industry. In the field of upstream life sciences equipment, Bogong Technology has elevated import substitution to the stage of global innovation. Based on a profound understanding of life science applications, and driven by novel design concepts as well as innovative equipment, software, and supporting technologies, the company is promoting the development and advancement of artificial intelligence in the life sciences and healthcare sectors. Qingcheng Capital is delighted to participate in this industrial progress.
Zhu Yu, Founding Partner of Rongzhen CapitalStatement: Rongzhen Capital is deeply honored to participate in the investment in Bogong Technology. We greatly admire the founding team’s commitment to independent R&D, their profound industry insights, and their strong capability in resource integration. We remain optimistic about the company’s future development and believe that, with capital support, Bogong Technology will soon emerge as a promoter and leader in the international arena of AI-driven life data management systems.
Dr. Tao Li, Stem Cell ScientistStatement: During my years as a shareholder of Bogong Technology, I have witnessed the company’s increasing maturity in team building, product development, and supply chain layout. I expect and believe that the company’s existing products will continue to grow steadily, while its newly launched products will rapidly scale up. Over the past year, the Bogong Technology team achieved outstanding results through strong execution, delivering counter-trend performance growth in a highly challenging environment. The team developed multiple product lines with significant growth potential, further solidifying its leading position in the industry for AI-powered life science data management solutions. Moving forward, I will continue to support the company’s R&D strategy by leveraging my extensive resources in the life sciences and healthcare sector, helping to establish Bogong Technology as a globally recognized sci-tech innovation enterprise.